RxDoctor Payments Data

Caroline Kurtz, MD

Pulmonary Disease · Norwalk, CTNPI 1720172836

Payments from drug & device makers

$3,269in general payments, 2019–2025

Across 53 payments — averaging $61.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$2K
  • Smith+Nephew$335
  • Organogenesis Inc.$271
  • AstraZeneca$181
  • Regeneron Healthcare Solutions, Inc.$110
  • Lilly USA, LLC$66
  • plus $286 from 9 others

What the payments were for

  • Consulting fees$1,76554%
  • Travel & lodging$983%
  • Food & beverage$1,31440%
  • Education$923%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,269 in reported general payments places this provider in the 60th percentile of 255 pulmonary disease providers in Connecticut.

See all pulmonary disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$117,465
Medicare patients
314
Services billed
1,435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab30$132,472
Trelegy ElliptaFluticasone/Umeclidin/Vilanter99$114,002
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr117$92,891
Breo ElliptaFluticasone/Vilanterol93$55,743
Spiriva RespimatTiotropium Bromide30$28,074
Spiriva HandihalerTiotropium Bromide30$25,525
EliquisApixaban28$23,584
Arnuity ElliptaFluticasone Furoate39$19,436
SymbicortBudesonide/Formoterol Fumarate57$19,120
Advair HfaFluticasone Propion/Salmeterol29$16,034
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$14,994
Incruse ElliptaUmeclidinium Bromide16$11,542
Pirfenidone12$10,453
Bevespi AerosphereGlycopyrrolate/Formoterol Fum20$10,088
Varenicline Tartrate35$8,547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta$11$293,615364 claims
AstraZenecaSymbicort, Breztri Aerosphere, Bevespi Aerosphere$181$44,20293 claims
Boehringer IngelheimSpiriva Respimat$2,021$28,07430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 255 pulmonary disease providers in Connecticut.

Other pulmonary disease in Norwalk

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →